Efzimfotase alfa demonstrated improvements in bone health in treatment-naïve pediatric patients with hypophosphatasia achieving median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase III trial
Flagship Pioneering and Lean Business Services Company Announce Collaboration to Advance Healthcare Innovation and AI-Enabled Biomedical Research in Saudi Arabia